4 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on Therapy Areas to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Aphasia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 14 ongoing clinical trials involving Aphasia
Of the 14 trials,6 trials are in Phase II
Furthermore, 2 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Aphasia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Aphasia, a Central Nervous System indication. The highest number of ongoing clinical trials involving Aphasia is in Asia-Pacific. North America and Europe are among some of the other prominent regions involved in Aphasia-related drug trials.

Axon Neuroscience SE: The leading ongoing Aphasia-related clinical trials sponsor

Axon Neuroscience SE, a Slovakia-based biotech company, is the top sponsor for Aphasia-related ongoing clinical trials.

Kessler Foundation, Xi'an Jiaotong University Hospital 1, Zhejiang University School of Medicine Hospital 2, University of Sydney, and Shenzhen Traditional Chinese Medicine Hospital are a few other notable sponsors involving Aphasia.

A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Aphasia

Fursultiamine (Bitafant F) is the sole key marketed drug involving Asthma.

Fursultiamine (Bitafant F) is a disulfide derivative of thiamine (Vitamin B1Fursultiamine improves the physiological, biochemical deficiency and metabolic disturbances and neurological dysfunction that is related to vitamin B1, the myocardial metabolic disorder is absorbed into the cells better than vitamin B1 and generates a large amount of active vitamin co- carboxylase. It is formulated as tablets for the oral route of administration and as a powder for solution for intravenous administration. Bitafant F is indicated for the prevention and treatment of vitamin B1 deficiency and wernicke's encephalopathy. Fursultiamine was first approved in 1998 and is marketed in Japan by several prominent pharma giants including Towa Pharmaceutical Co Ltd.

Explore the latest trends and actionable insights on Therapy Areas to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on Therapy Areas to inform business strategy and pinpoint opportunities and risks. Visit Report Store